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Abstract
The tumour microenvironment is complex and composed of many different
constituents, including matricellular proteins such as connective tissue growth
factor (CCN2), and is characterized by gradients in oxygen levels. In various
cancers, hypoxia and CCN2 promote stem and progenitor cell properties, and
regulate the proliferation, migration and phenotype of cancer cells. Our study was
aimed at investigating the effects of hypoxia and CCN2 on chordoma cells, using
the human U-CH1 cell line. We demonstrate that under basal conditions, U-CH1
cells express multiple CCN family members including CCN1, CCN2, CCN3 and
CCN5. Culture of U-CH1 cells in either hypoxia or in the presence of recombinant
CCN2 peptide promoted progenitor cell-like characteristics specific to the
notochordal tissue of origin. Specifically, hypoxia induced the most robust increase
in progenitor-like characteristics in U-CH1 cells, including increased expression of
the notochord-associated markers T, CD24, FOXA1, ACAN and CA12, increased
cell growth and tumour-sphere formation, and a decrease in the percentage of
vacuolated cells present in the heterogeneous population. Interestingly, the effects
of recombinant CCN2 peptide on U-CH1 cells were more pronounced under
normoxia than hypoxia, promoting increased expression of CCN1, CCN2, CCN3
and CCN5, the notochord-associated markers SOX5, SOX6, T, CD24, and FOXA1
as well as increased tumour-sphere formation. Overall, this study highlights the
importance of multiple factors within the tumour microenvironment and how hypoxia
and CCN2 may regulate human chordoma cell behaviour.
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Introduction
Chordomas are rare, malignant and locally invasive tumours that originate in
bones of the skull and spine, and are thought to arise from cellular remnants of
the embryonic notochord. These tumours occur most commonly at the base of
the skull (32%) and sacrococcygeal region (29%), and less frequently in cervical,
thoracic and lumbar vertebrae [1, 2]. The cancer typically affects one in one
million people each year in the United States, with the median age of diagnosis
being 49 years for skull-based chordomas and 69 years for sacral-based chordomas
[2].
During embryonic development, notochord cells act as tissue-specific
progenitor cells that give rise to the nucleus pulposus of the intervertebral disc
[3, 4]; however, during spine formation and notochord segmentation some of
these notochord cells get trapped within the vertebral bone and are referred to as
benign notochord remnants. Since these benign notochord remnants give rise to
chordomas, it has been suggested that factors associated with the regulation of
embryonic notochord development may likewise be associated with malignant
transformation and the development of chordomas [5]. For example, studies have
demonstrated that brachyury (T), a transcription factor necessary for the
formation and maintenance of the notochord [6], is amplified in sporadic
chordomas and duplicated in familial chordomas [7, 8, 9]. In addition to T, other
transcription factors have been implicated in notochord development such as the
SOX (SRY-type high mobility group box) family members SOX5, SOX6 and
SOX9 [10, 11] and the forkhead box proteins A1 and A2 (FOXA1 and FOXA2)
[12].
There are a limited number of studies that have examined the effects of the
tumour microenvironment on human chordoma cell biology. Two important
components of the tumour microenvironment are the oxygen concentration and
matricellular proteins, including CCN proteins. Hypoxic conditions (usually
between 1–3% O2 but vary depending on the type of tumour [13]) often result
from inadequate oxygen supply to the tumour, which can be caused by low
oxygen tension in arterial blood, limited ability for blood to carry oxygen, reduced
tissue perfusion or inconsistencies in blood flow diffusion [14]. Normally, these
conditions are detrimental to cells, but cancer cells adapt to the hypoxic
environment. For example, under hypoxia prostate cancer cells show increased
cell proliferation [15], and prostate [15], breast [16] and colon [17] cancer cells
display increased migration compared to cells cultured under normoxia. In
addition, studies have shown that hypoxia can promote stem and progenitor cell
properties in various cancers including glioma, glioblastoma and ovarian cancer
[18, 19].
Connective tissue growth factor (CCN2; formerly known as CTGF) is part of
the CCN family of matricellular proteins. CCN2 is expressed in many tissues
including the notochord [20] and nucleus pulposus [21] and is an important
regulator of notochord development [22]. CCN2 also has a role in cancer cell
biology and has been shown to promote cell proliferation, colony formation,
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migration and angiogenesis in a cell type-specific manner [23]. CCN2 has also
been shown to modulate stem and progenitor cell properties; mesenchymal stem
cells treated with recombinant CCN2 (rCCN2) demonstrated reduced differentiation, whereas the addition of rCCN2 to hepatic progenitor cells promoted
hepatocytic differentiation [24, 25].
The specific effects of hypoxia and CCN2 on chordoma cells are largely
unknown. Studies have demonstrated that a large volume of chordoma tumours
are hypoxic [26] and that CCN2 is a direct downstream target of T in chordoma
[27]. In this study, we sought to better understand the role of the tumour
microenvironment by specifically investigating the effects of hypoxia and CCN2
on the regulation of chordoma cells using the human U-CH1 cell line [28].
Through characterization of gene expression and functional analyses, we
demonstrate that exposure of U-CH1 cells to hypoxic conditions or recombinant
CCN2 peptide promoted progenitor-like characteristics specific to the notochordal tissue of origin. Interestingly, exposure of chordoma cells to hypoxia
induced more pronounced changes in in vitro cell behaviour than did exposure of
cells to CCN2. Furthermore, we found an additive effect on the expression of a
subset of notochord progenitor markers by U-CH1 cells when CCN2 and hypoxia
were combined in the cell microenvironment.

Materials and Methods
Cell culture
All experiments were conducted using the human U-CH1 chordoma cell line [28].
Cells were maintained using previously established protocols in IMDM/RPMI
(4:1) (Invitrogen, Life Technologies) supplemented with 10% fetal bovine serum
(Invitrogen, Life Technologies) (chordoma media) on 0.1% gelatin coated cell
culture plates. U-CH1 cells were maintained in monolayer cultures and passaged
by enzymatic dissociation at a ratio of 1:3–1:6 for cell expansion. Recombinant
human CCN2 (PHG0286, Life Technologies) was resuspended in 0.1% bovine
serum albumin in PBS. This 11.2 kDa peptide fragment corresponds to amino
acids 253–349 of the full length human CCN2 and contains the cysteine knot
domain. U-CH1 cells were treated with 50, 100 or 200 ng/mL rCCN2 in IMDM/
RPMI (4:1) with 5% FBS. All cell culture was carried out at 37 ˚C in a humidified
atmosphere of 5% CO2 in either normoxic (20% O2) or hypoxic (2% O2)
conditions. Cells were maintained for at least 1–2 passages in either normoxia or
hypoxia before experiments were performed.

Immunocytochemistry
Confluent monolayer cultures of U-CH1 cells cultured on glass-bottom culture
dishes (MatTek Corporation) were fixed in 4% paraformaldehyde (37 ˚C) for
10 min. Cells were washed three times in 0.1% Triton X-100 in PBS (PBST) and
then blocked using 5% species-specific serum in PBST for 1 h at room
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temperature. Cells were then incubated overnight at 4 ˚C in 5% species-specific
serum in PBST containing primary antibodies against human CCN1 (1:200;
sc13100, Santa Cruz Biotechnology), CCN2 (1:200; sc14939, Santa Cruz
Biotechnology), brachyury (1:400; sc17743, Santa Cruz Biotechnology) or HIF-1a
(1:100; 07–628, Millipore). Cells were washed and incubated with fluorescenceconjugated secondary antibodies (donkey anti-goat IgG (A11055), goat antirabbit IgG (A11008) or donkey anti-mouse IgG (A11001), Life Technologies). For
nuclear staining, 1 ug/mL Hoechst 33258 (Sigma-Aldrich) was added in PBST for
10 min. IgG and secondary only controls were run in parallel with experimental
samples to detect non-specific binding. Images were acquired using a Leica
Microsystems DM16000B fluorescent microscope and DFC360FX camera.

Real-time PCR
Cells were harvested directly in TRIzol Reagent (Life Technologies). Total RNA
was extracted according to the manufacturer’s protocol and quantified using a
NanoDrop 2000 spectrophotometer (Thermo Scientific). For each sample, 0.5 mg
RNA was used for cDNA synthesis (iScript, Bio-Rad Laboratories). Real-time PCR
was performed using the Bio-Rad CFX384 system. PCR reactions were run in
triplicate using 27 ng of cDNA per reaction and 310 nM forward and reverse
primers (sequences provided in Table 1) with 2X SsoFast EvaGreen Supermix
(Bio-Rad Laboratories). The PCR program was an initial 2 min at 95 ˚C followed
by 40 cycles of 10 sec at 95 ˚C, and 20 sec annealing/elongation at 60 ˚C. Gene
expression was normalized relative to a standard curve (1/5 serial dilution with
initial input of 0.1 mg/mL) made from a mixture of cDNA generated from U-CH1
cells, human foreskin fibroblast cells and human embryonic stem cells in a 2:2:1
ratio.

Cell growth assay
U-CH1 cells were plated at a density of 3,430 cells/cm2 in chordoma media or
rCCN2 media and maintained under either normoxic or hypoxic conditions.
Every 24 h over 8 days, cells were trypsinized and counted in triplicate with a
hemocytometer on a phase contrast light microscope using Trypan Blue (Gibco)
to exclude non-viable cells.

Cell migration assay
U-CH1 cells were plated in chordoma media at 25,714 cells/cm2 and maintained
under either normoxic or hypoxic conditions. After 24 h, media was changed to
IMDM/RPMI (4:1) with 0.2% FBS to permit cell survival but minimize cell
proliferation. After 24 h, an artificial ‘‘scratch wound’’ was created using a pipette
tip. Cells were imaged at 0, 12, 24, 36 and 48 h at the location of the scratch.
Images were exported to ImageJ software and the polygon selection tool was used
to calculate the area of new cell migration at each time point. The percentage of
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Table 1. Primer sequences used for real-time PCR gene expression analysis.
Gene Name

Primer Sequence (59 to 39)

CCN1

Fwd- ACCGCTCTGAAGGGGATCT Rev- ACTGATGTTTACAGTTGGGCTG

CCN2

Fwd- TCCCAAAATCTCCAAGCCTA Rev- GTAATGGCAGGCACAGGTCT

CCN3

Fwd- AGTGATGGTCATTGGGACCTG Rev- CCTCTGGTAGTCTTCAGCTCC

CCN5

Fwd- GCGACCAACTCCACGTCTG Rev- TCCCCTTCCCGATACAGGC

Brachyury (T)

Fwd- TGAGACCCAGTTCATAGCGG Rev- TGCTGGTTCCAGGAAGAAGC

CD24

Fwd- CTCCTACCCACGCAGATTTATTC Rev- AGAGTGAGACCACGAAGAGAC

ACAN

Fwd- TGAGGAGGGCTGGAACAAGTACC Rev- GGAGGTGCTAATTGCAGGGAACA

FOXA1

Fwd- GCAATACTCGCCTTACGGCT Rev- TACACACCTTGGTAGTACGCC

CA12

Fwd- TGGCATTCTTGGCATCTGTA Rev- TTGGTGGCTGGCTTGTAAAT

SOX5

Fwd- CAGCCAGAGTTAGCACAATAGG Rev- CTGTTGTTCCCGTCGGAGTT

SOX6

Fwd- TACCTCTACCTCACCACATAAGC Rev- ACATCGGCAAGACTCCCTTTG

SOX9

Fwd- AGCGAACGCACATCAAGAC Rev- CTGTAGGCGATCTGTTGGGG

HIF1A

Fwd- ATCCATGTGACCATGAGGAAATG Rev- TCGGCTAGTTAGGGTACACTTC

VEGFA

Fwd- AGGGCAGAATCATCACGAAGT Rev- AGGGTCTCGATTGGATGGCA

GLUT1

Fwd- GGCCAAGAGTGTGCTAAAGAA Rev- ACAGCGTTGATGCCAGACAG

doi:10.1371/journal.pone.0115909.t001

wound closure was calculated using the formula [(Areat-0h – Areat-Dh)/Areat-0h]
6100%, as previously reported [29].

Sphere formation assay
U-CH1 cells were plated using standard protocols for tumour-sphere formation,
at 1,500 cells/well in 24-well non-adherent plates (Nunc, Thermo Scientific) and
grown for 10 days in serum-free DMEM/F12 (Life Technologies) supplemented
with B27 (1:50 dilution), bFGF (20 ng/mL), EGF (20 ng/mL) and 1%
methylcellulose (R&D Systems). For rCCN2 experiments, the above media was
supplemented with 100 ng/mL rCCN2. Cells were fed every other day and spheres
(defined as $50 mm) were counted after 10 days. The efficiency of sphere
formation (number of spheres per 1000 cells) was calculated, as previously
described [30].

Flow cytometry
U-CH1 cells were harvested from monolayer by enzymatic dissociation in 0.25%
Trypsin and resuspended in 10% FBS in PBS. Cells were resuspended at 16106
cells/mL in Aldefluor buffer (Stemcell Technologies). 2 mL/mL Aldefluor reagent
(Stemcell Technologies) was added to determine aldehyde dehydrogenase
(ALDH) activity, with an ALDH inhibitor (diethylaminobenzaldehyde (DEAB))
as a negative control (Stemcell Technologies). Samples were incubated for 30 min,
pelleted by centrifugation (470 g, 7 min) and resuspended in Aldefluor buffer
(16106 cells in 200 mL) with fluorochrome-conjugated antibodies specific to
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human CD90 (555596, BD Biosciences), CD105 (562380, BD Biosciences), CD133
(130090826, Miltenyi Biotec) or IgG controls for 30 min. After incubation, ALDH
and cell surface expression was assessed in a minimum of 100,000 cells/treatment
group, using a LSR II flow cytometer (BD Biosciences) at the London Regional
Flow Cytometry Facility, and analyzed on FlowJo software program. U-CH1 cells
were characterized based on side scatter using cluster gating, as previously
described [31].

Statistical analysis
All data was collected and statistical analysis was performed using GraphPad
Prism 6.0 Software. Data was analyzed using either unpaired Student’s t test
(between 2 groups), 1-way ANOVA (between $3 groups; comparing one
condition) or 2-way ANOVA (between $3 groups; comparing two conditions)
with either a Tukey’s multiple comparisons test or Dunnett’s test to examine
differences compared to a control group.

Results
Expression of T and CCN proteins in U-CH1 cells
The expression of the known chordoma marker brachyury (T) and the
matricellular proteins CCN1 and CCN2 were first assessed in U-CH1 cells. In
keeping with previous reports [32], immunolocalization demonstrated expression
and nuclear localization of T in the majority of U-CH1 cells (both vacuolated and
non-vacuolated cell morphologies) (Fig. 1). We also detected expression of CCN1
and CCN2 in both vacuolated and non-vacuolated U-CH1 cells, localized to the
perinuclear and cytoplasmic regions of the cells (Fig. 1).

Effects of hypoxia on U-CH1 gene expression
To determine the effects of changes in oxygen levels in the cell microenvironment
on the chordoma cell gene expression profile, U-CH1 cells were grown in either
normoxic (20% O2) or hypoxic (2% O2) conditions and a panel of genes were
investigated. We first assessed expression of CCN family members, CCN1 [33],
CCN2 [34, 35], CCN3 [36] and CCN5 [37, 38] which have been implicated in
modulating cell proliferation, cell adhesion, angiogenesis, cell migration,
metastasis and epithelial-mesenchymal transition in a variety of cancers. While no
change in CCN1 or CCN2 expression was detected, culture of U-CH1 cells in
hypoxia promoted a significant increase in the expression of CCN3 and CCN5
compared to normoxia (Fig. 2A). We next investigated the expression of SOX
family members SOX5, SOX6 and SOX9. Culture of cells in hypoxia induced a
significant increase in SOX6 and SOX9 expression in U-CH1 cells compared to
cells maintained in normoxia (Fig. 2B). To determine if the expression of early
notochord progenitor markers was altered in U-CH1 cells under hypoxic
conditions, we examined the expression of T, CD24, FOXA1, ACAN and CA12
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Fig. 1. Localization of T, CCN1 and CCN2 in U-CH1 cells. Representative images demonstrating the
localization of T, CCN1 and CCN2 in U-CH1 cells. For each, protein expression was detected in both
vacuolated (arrow) and non-vacuolated (arrowhead) cells in the heterogenous cell population. (n53; N53;
scale bar5100 mm).
doi:10.1371/journal.pone.0115909.g001

(Fig. 2C). Culture of U-CH1 cells in hypoxia induced a significant up-regulation
in the expression of all these markers, with T and CA12 having the most
significant increase (P,0.001) followed by CD24 and ACAN (P,0.01) and then
FOXA1 (P,0.05). Lastly, to determine if HIF-1a was activated in U-CH1 cells
under hypoxic conditions, we interrogated the expression of HIF1A and its
downstream targets VEGF-A and GLUT1 (Fig. 2D). Although no change was
detected in the expression of HIF1A, chordoma cells demonstrated a significant
increase in the expression of both VEGF-A and GLUT1 in hypoxia compared to
cells maintained in normoxia.

Changes in CCN1 localization in hypoxia
Protein localization in U-CH1 cells maintained in either hypoxic or normoxic
conditions was directly compared (Fig. 3). In normoxia, perinuclear and diffuse
cytoplasmic CCN1 staining was detected in U-CH1 cells. In contrast, CCN1
appeared to be concentrated at the cell periphery in U-CH1 cells maintained in
hypoxia. HIF-1a was detected primarily in the nucleus of U-CH1 cells under both
normoxia and hypoxia. No changes were detected in the localization of either
CCN2 or T in U-CH1 cells maintained in hypoxia compared to cells maintained
in normoxia.

PLOS ONE | DOI:10.1371/journal.pone.0115909 December 26, 2014

7 / 22

Microenvironmental Regulation of U-CH1 Chordoma Cells

Fig. 2. Effect of hypoxia on gene expression in U-CH1 cells. Gene expression was assessed in U-CH1 cells maintained for at least 2 passages in either
normoxic (20% O2) or hypoxic (2% O2) conditions by real-time PCR. Expression of (A) members of the CCN family (CCN1, CCN2, CCN3, CCN5), (B)
members of the SOX transcription factor family (SOX5, SOX6, SOX9), (C) notochord markers (CD24, T, AGG, FOXA1, CA12) and (D) hypoxia inducible
factor (HIF1A) and its downstream targets (VEGF-A, GLUT1) were investigated. Data is presented as the mean ¡SEM, changes assessed using unpaired
Student’s t test; *5P#0.05, **5P#0.01, ***5P#0.001, ****5P#0.0001 (n53; N53–4).
doi:10.1371/journal.pone.0115909.g002
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Fig. 3. Expression and localization of T, CCN1, CCN2 and HIF-1a in U-CH1 cells maintained under
normoxic (20% O2) or hypoxic (2% O2) conditions. Representative images demonstrating changes in the
localization of target proteins in U-CH1 cells cultured in hypoxia. CCN1 demonstrates diffuse nuclear and
cytoplasmic localization under normoxia but is concentrated to the cytoplasmic and cell periphery in cells
under hypoxia. HIF-1a demonstrates primarily nuclear localization. CCN2 is localized to the nuclear and
cytoplasmic region, and T is localized to the nuclear region under both normoxia and hypoxia. (n53; N53;
scale bar 5100 mm).
doi:10.1371/journal.pone.0115909.g003

Hypoxia promotes U-CH1 cell growth and sphere formation but
reduces cell migration
To investigate cell growth, U-CH1 cells were counted every 24 h over 8 days in
either normoxic or hypoxic conditions (Fig. 4A). U-CH1 cells demonstrated
increased growth in hypoxia compared to cells maintained in normoxia at days 6,
7 and 8. In addition to changes at specific time points, there was a significant
increase in the rate of cell growth under hypoxia compared to normoxia, as
determined by linear regression analysis. To investigate stem-like properties,
tumour-sphere formation assays were conducted with U-CH1 cells under
normoxic or hypoxic conditions (Fig. 4B). Quantification of the efficiency of
sphere formation following 10 days of culture demonstrated a significant 10-fold
increase in sphere formation in U-CH1 cells maintained in hypoxia compared to
cells maintained in normoxia. To evaluate changes in U-CH1 cell migration in
hypoxia compared to normoxia, a ‘‘scratch wound’’ assay was conducted and cell
migration was assessed over 48 h (Fig. 4C). U-CH1 cells maintained in hypoxia
demonstrated a significant decrease in cell migration at 12, 24 and 36 h compared
to cells maintained in normoxia. This difference was no longer apparent at 48 h,
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Fig. 4. Cell growth, migration and tumour-sphere formation in U-CH1 cells in normoxic (20% O2) or hypoxic (2% O2) conditions. (A) U-CH1 cells
were counted every 24 h over 8 days and demonstrate increased growth in hypoxia versus normoxia at days 6–8 (n53; N53). (B) U-CH1 cells were grown
in suspension and spheres were counted after 10 days. Cells maintained under hypoxic conditions demonstrate a significant increase in sphere formation
compared to cells maintained in normoxic conditions (N53; scale bar5250 mm). (C) U-CH1 cells were plated and an artificial ‘‘scratch wound’’ was created.
Cells were imaged at 12, 24, 36 and 48 h and the area of new cell migration borders was determined. Maintenance of cells in hypoxia significantly
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decreased cell migration at 12, 24 and 36 h compared to cells in normoxia at the same time-point (n54; N54). (2-way ANOVA with Tukey’s test (A and C);
Unpaired Student’s t test (B); *5P#0.05; **5P#0.001; ***5P#0.0001; scale bar5250 mm).
doi:10.1371/journal.pone.0115909.g004

as the majority of the wound appeared to be closed under both conditions. Taken
together, these findings suggest that hypoxia could be promoting progenitor celllike properties in U-CH1 cells.

rCCN2 peptide promotes ACAN and COL2A1 gene expression in
U-CH1 cells
Previous studies demonstrated the up-regulation of ACAN and COL2A1 gene
expression in nucleus pulposus cells following stimulation with rCCN2 [39, 40].
To ensure bioactivity of the 11.2 kDa rCCN2 peptide in UCH-1 cells, we
quantified expression of ACAN and COL2A1 in UCH-1 cells following 24 h
treatment with 50, 100 or 200 ng/mL rCCN2. Treatment of cells with 100 ng/mL
rCCN2 resulted in a significant increase in ACAN and COL2A1 expression under
both normoxia and hypoxia. Treatment of cells with 200 ng/mL rCCN2 increased
the expression of COL2A1, however this effect was only significant under
normoxia (S1 Fig.). A concentration of 100 ng/mL rCCN2 was therefore used in
all subsequent experiments.

Effects of rCCN2 peptide on U-CH1 gene expression under
normoxia and hypoxia
To determine the effects of CCN2 on chordoma cells, U-CH1 cells were treated
with rCCN2 peptide under either normoxic or hypoxic conditions for 24 h, and a
panel of genes was investigated. We first assessed the expression of CCN1, CCN2,
CCN3 and CCN5 and found a significant increase in all of these genes with the
addition of rCCN2 under either normoxia or hypoxia (Fig. 5A). We also assessed
the expression of SOX family members and found a significant increase in SOX5
and SOX6 gene expression with the addition of rCCN2 under normoxia, but no
change was detected when rCCN2 was added to cells in hypoxia (Fig. 5B). Lastly,
we investigated the expression of early notochord markers (Fig. 5C). U-CH1 cells
treated with rCCN2 in normoxia demonstrated a significant increase in the
expression of T, CD24, FOXA1 and ACAN compared to untreated controls. In
hypoxia, treatment of U-CH1 cells with rCCN2 induced a significant increase in
the expression of T, CD24 and ACAN compared to untreated controls.
Interestingly, rCCN2 and hypoxia induced an additive response in the expression
of a subset of genes in U-CH1 cells, specifically T, CD24 and ACAN. Together,
these data suggest that rCCN2 peptide may be promoting a progenitor cell-like
phenotype in U-CH1 cells, with the effects being more robust under normoxia
than hypoxia.
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Fig. 5. Effect of rCCN2 peptide on U-CH1 gene expression in normoxic (20% O2) or hypoxic (2% O2) conditions. Expression of (A) members of the
CCN family (CCN1, CCN2, CCN3, CCN5), (B) members of the SOX transcription factor family (SOX5, SOX6, SOX9) and (C) notochord markers (T, CD24,
FOXA1, ACAN, CA12) were investigated in U-CH1 cells treated with 100 ng/mL of rCCN2 for 24 h in either normoxic or hypoxic conditions. Data is
presented as the mean ¡SEM, assessed using an Unpaired Student’s t test; n53, N53; *5P#0.05, **5P#0.01, ***5P#0.001, ****5P#0.0001.
doi:10.1371/journal.pone.0115909.g005

rCCN2 peptide increases U-CH1 tumour-sphere formation but
does not increase cell growth
Sphere formation was assessed for U-CH1 cells grown in either normoxia or
hypoxia with the addition of rCCN2 for 10 days. U-CH1 cells demonstrated a
significant 1.7-fold increase in tumour-sphere formation with the addition of
rCCN2 in normoxia compared to vehicle control. In contrast, treatment of UCH1 cells with rCCN2 in hypoxia did not alter sphere formation compared to
vehicle control (Fig. 6A). We then assessed U-CH1 cell growth in the presence of
rCCN2 in normoxia, as these culture conditions more significantly induced
changes in U-CH1 cell properties. Over 8 days, treatment of U-CH1 cells with
rCCN2 did not alter cell growth (Fig. 6B). We also performed a linear regression
analysis and found no changes in the rate of cell growth between U-CH1 cells
treated with rCCN2 and vehicle control.

Maintenance of U-CH1 cells in hypoxia leads to a decrease in the
number of vacuolated cells
To determine if culture of U-CH1 cells in hypoxia or the treatment of cells with
rCCN2 peptide affected the morphological characteristics of the heterogeneous
chordoma cell population, we assessed intracellular complexity of cells by flow

Fig. 6. Sphere formation and cell growth in U-CH1 cells treated with rCCN2. (A) Sphere formation was assessed in U-CH1 cells treated with rCCN2
(100 ng/mL) in either normoxic or hypoxic conditions. The efficiency of sphere formation was assessed at day 10 as the number of spheres formed per 1000
cells. Data is presented as fold change from vehicle control (set to 1; indicated by dashed line) for cells maintained in either normoxic or hypoxic culture
conditions. Treatment of cells with rCCN2 induced a significant increase in sphere formation compared to vehicle control when cells were maintained in
normoxia (N53–4). (B) U-CH1 cells were maintained in normoxic conditions and treated with 100 ng/mL of rCCN2 or vehicle control and cell number was
quantified every 24 h over 8 days. No change in cell growth was detected following treatment with rCCN2 compared to vehicle control (n53, N53). Unpaired
Student’s t test (A); 2-way ANOVA with Tukey’s test (B); *5P#0.05; scale bar5250 mm.
doi:10.1371/journal.pone.0115909.g006
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Fig. 7. Side scatter distribution of U-CH1 cells maintained in normoxic (20% O2) or hypoxic (2% O2)
conditions, with or without rCCN2. Cluster gating was used to determine the intracellular complexity of
UCH-1 cells. Cells demonstrated a significant decrease in the number of vacuolated cells (side scatter high)
under hypoxia compared to normoxia with minimal changes detected following culture of cells for 6 days in the
presence of 100 ng/mL rCCN2 (N53).
doi:10.1371/journal.pone.0115909.g007
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cytometry. Recent studies have suggested that non-vacuolated chordoma cells
represent the progenitor cells within the heterogeneous population, giving rise to
the characteristic larger vacuolated chordoma cells [41]. We first assessed U-CH1
cells maintained in either normoxia or hypoxia and found a significant decrease in
the percentage of vacuolated U-CH1 cells (high side scatter) in hypoxia compared
to cells maintained in normoxia (3.8¡0.6% vs. 6.0¡0.3%, respectively).
Interestingly, treatment of cells with rCCN2 over 6 days did not alter the
percentage of vacuolated U-CH1 cells in either normoxia (5.7¡0.9% vehicle vs.
5.8¡1.1% rCCN2) or hypoxia (3.7¡0.6% vehicle vs. 3.9¡0.4% rCCN2) (Fig. 7).
To investigate if a cancer stem cell population could be detected in U-CH1 cells,
the expression of CD133 and the activity of aldehyde dehydrogenase (ALDH),
common markers of cancer stem cells [42, 43, 44, 45, 46], were examined in cells
maintained in either normoxia or hypoxia, with our without the addition of
rCCN2. We detected minimal expression of CD133 (.0.01% positive cells) and
minimal ALDH activity (.0.02% ALDHhi cells) in U-CH1 cells under all culture
conditions examined. We further investigated expression of the cell surface
markers CD90 and CD105 which were previously detected in U-CH1 cells [47]
and act as differentiation markers in mesenchymal stromal cells [48]. No
significant change in the percentage of CD90+ or CD105+ cells was detected when
U-CH1 cells were maintainted in normoxic or hypoxic conditions, with or
without the addition of rCCN2 (S2 Fig.).

Discussion
The tumour microenvironment is composed of a variety of different cell types
such as cancer cells, stromal fibroblasts, endothelial cells, whose function is
modulated by oxygen levels, the extracellular matrix and secreted proteins,
including CCN proteins [49]. The current study investigated the effects of hypoxia
and the matricellular protein CCN2 on U-CH1 cells, as there is strong indication
that these factors could be involved in the regulation of chordoma cell biology
[26, 27]. In this study, we demonstrate that U-CH1 cells express multiple CCN
proteins and show that their expression is regulated by the chordoma
microenvironment. Using a combination of gene expression analysis and in vitro
functional assays, we found that hypoxia had the greatest ability to promote
progenitor-like properties in U-CH1 cells compared to treatment of cells with
rCCN2 peptide. In addition, we demonstrated that the effects of rCCN2 and
hypoxia were additive for the expression of a specific subset of notochord
progenitor markers.
In this study, we demonstrate the expression of CCN matricellular proteins in
U-CH1 cells through immunolocalization and gene expression analysis. To our
knowledge, this is the first investigation of CCN protein expression in chordoma
cells and suggests they could have a potential role as regulators of chordoma cell
biology. Through gene expression analysis, we detected expression of CCN1,
CCN2, CCN3 and CCN5 in U-CH1 cells under basal conditions, and demonstrate
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increased expression of CCN3 and CCN5 by chordoma cells in hypoxia. These
findings are in keeping with previous studies that reported increased expression of
CCN1 and CCN3 in human choriocarcinoma cells [50], increased expression of
CCN1 in retinal vascular endothelial cells [51], and increased expression of CCN2
in primary tubular epithelial cells [52]cultured in hypoxia compared to cells
cultured in normoxia. Interestingly, we also detected changes in the localization of
CCN proteins in U-CH1 cells depending on the oxygen levels in their culture
environment, including nuclear localization of both CCN1 and CCN2. Previous
studies have reported similar nuclear localization of CCN proteins in cancer cells,
including nuclear localization of CCN1 in prostate carcinoma [53] and breast
cancer cells [54] and the nuclear localization of CCN2 in melanoma cells [55].
While the cellular function of CCN proteins within the nucleus remains unknown,
the report of their nuclear localization in multiple studies suggests they may
perform additional cellular functions. For example, a truncated form of CCN3
lacking the secretory signal peptide is directed to the nucleus and has been shown
to exhibit negative transcriptional activity [56]. Similarly, after binding at the cell
surface, CCN2 can be transported via endocytosis to the nucleus, although its
function there remains unknown [57].
When U-CH1 cells were maintained in hypoxia, we found an increase in the
expression of notochord markers (T, CD24, FOXA1, ACAN and CA12), tumoursphere formation and cell growth, and a decrease in cell migration. Our findings
are consistent with recent molecular profiling of chordoma cells that identified
CD24 in a list of potential candidates for chordoma tumorigenesis [9]. There are
currently opposing reports as to the effects of hypoxia on human chordoma cell
growth [58, 59]. Our findings are consistent with those of Ostroumov et al., which
reported an increase in cell growth in a primary human chordoma cells in hypoxia
compared to normoxia. The decrease in cell migration detected in U-CH1 cells in
hypoxia contrasts reports showing that hypoxia increases the migratory potential
of various cancer cell types, including glioma [60], epithelial ovarian cancer [61],
breast cancer [62] and gastric cancer cells [63]. It is tempting to speculate that this
response may be related to properties of the notochordal cell type from which
chordomas are derived, which adapt to survive within the hypoxic environment of
the intervertebral disc during normal development [64]. Further validating a
change in U-CH1 cell phenotype in hypoxia, we demonstrated a decrease in the
number of vacuolated U-CH1 cells in hypoxia compared to normoxia. These
findings are in keeping with a recent study suggesting that vacuolated cells
represent a more differentiated cell type within the heterogeneous U-CH1 cell
population [41]. Our findings are also in line with studies in other cancers which
reported the promotion of stem and progenitor cell properties following culture
of cells in hypoxia [19, 65].
In hypoxia, cells typically demonstrate increased activity of HIF-1a, a
transcription factor that binds to hypoxia-response elements to activate the
expression of genes that regulate proliferation, angiogenesis, metabolism,
apoptosis and the maintenance of an undifferentiated state in cancer cells
[66, 67, 68]. For example, vascular endothelial growth factor (VEGF) and glucose
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transporter 1 (GLUT1) are direct downstream targets of HIF-1a involved in
angiogenesis and glycolysis, respectively [69]. Under normoxic conditions, the a
subunit of the HIF-1a protein is rapidly degraded through hydroxylation of two
key proline residues in the oxygen-dependent degradation domain [70]. However,
under hypoxic conditions, HIF-1a becomes stabilized, translocates to the nucleus,
and dimerizes with the aryl hydrocarbon receptor nuclear translocator (ARNT)
binding to the HIF-1 consensus sequence to activate hypoxia-inducible genes.
Recent studies have reported HIF-1a expression in the majority of chordoma
samples examined, correlated with VEGF expression and tumour microvessel
density [18, 71]. While we did not detect the induction of HIF1A gene expression
in U-CH1 cells maintained in hypoxia, we detected a significant up-regulation of
VEGF-A and GLUT1 gene expression, suggesting increased HIF-1a activity in
hypoxia.
Compared to the effects of hypoxia on U-CH1 cells, we found that treatment of
cells with exogenous CCN2 induced the expression of fewer notochord markers
(T, CD24, FOXA1 and ACAN) and SOX family members (SOX5, SOX6). Along
with changes in gene expression, we found an increase in sphere formation but no
changes in cell growth. Interestingly, we found that addition of rCCN2 peptide to
cells grown in hypoxia induced even fewer changes in the expression of notochord
progenitor markers, no change in the expression of SOX family members, and did
not promote sphere formation. These differences in the effect of exogenous CCN2
treatment in normoxic or hypoxic conditions may be related to the cell-type
specific effects of CCN proteins. We demonstrated that U-CH1 cells are more
progenitor-cell like under hypoxia than in normoxia. In these conditions, cells
may express a different profile of integrins, cell surface receptors or CCN binding
proteins that mediate CCN2-dependent signalling. Furthermore, recent studies
have established an intriguing direct feedback between HIF-1a and CCN2 in
related cell types. In chondrocytes, HIF-1a directly interacts with the Ccn2
promoter and the addition of rCCN2 increases HIF-1a mRNA and protein levels
[72]. In nucleus pulposus cells, the loss of HIF-1a was reported to increase CCN2
expression [73, 74, 75]. Based on these findings, we speculate that in addition to
independent CCN2 and HIF-1a induced pathways, there could be interaction
between HIF-1a and CCN2 in chordoma cells, such that rCCN2 is decreasing
HIF-1a activity under hypoxia but promoting HIF-1a activity under normoxia.
Taken together, findings from this study highlight the importance of the
tumour microenvironment in the regulation of human chordoma cell phenotype.
We demonstrate that components of the microenvironment influence the
chordoma cell phenotype and that cells respond to hypoxia and exogenous CCN2
by up-regulating progenitor cell-like properties. Although further studies are
required to validate these findings in other chordoma cell lines or primary tumour
cells, our findings suggest an intriguing commonality between the pathways
associated with notochord development and those associated with tumour
pathology. As has recently been suggested for other cancer types [76],
morphogens and extracellular signals that regulate embryonic notochord
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development may also play key roles in establishing a microenvironment that
promotes chordoma pathogenesis.

Supporting Information
S1 Fig. Effect of rCCN2 on ACAN and COL2A1 gene expression in U-CH1 cells
maintained in normoxic (20% O2) or hypoxic (2% O2) conditions. U-CH1 cells
were treated with 50, 100 or 200 ng/mL of rCCN2 for 24 h and harvested for gene
expression analysis. Treatment of cells with 100 ng/mL of rCCN2 promoted a
significant increase in ACAN and COL2A1 gene expression in cells under both
normoxia and hypoxia. Data is presented as the mean ¡SEM assessed using 1way ANOVA with Dunnet’s test; n53; N53; *5P#0.05; **5P#0.001.
doi:10.1371/journal.pone.0115909.s001 (TIF)
S2 Fig. Expression of cell surface markers CD90 and CD105 in U-CH1 cells
with or without rCCN2 in normoxic (20% O2) or hypoxic (2% O2) conditions.
Percentage of CD90+ and CD105+ cells U-CH1 cells as detected by flow cytometry.
Expression of CD90 and CD105 cells was detected in U-CH1 cells maintained
under normoxia and hypoxia, with no significant change in the expression of
these markers induced by either oxygen conditions or treatment with rCCN2
peptide. Data is presented as the mean ¡SEM; N53.
doi:10.1371/journal.pone.0115909.s002 (TIFF)
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